Compare Carnival Corp (CCL) vs DexCom, Inc. (DXCM) Price & Performance

Carnival Corporation (CCL) trades at $26.61, down 0.82% on the day, amid a bearish technical signal. The company demonstrates strong fundamental improvement with revenue growth to $26.62 billion in 2025 and net income of $2.76 billion, supported by three consecutive quarterly EPS beats. Positive analyst sentiment is evident with a $35.00 consensus price target and 59.57% buy ratings, while recent news highlights fleet expansion and strong bookings.

The outlook remains positive due to robust demand and cost controls, but risks include geopolitical tensions impacting fuel costs and softer European demand. The stock's current valuation metrics, such as a P/E of 11.99, suggest potential upside if execution continues, though investors must weigh debt levels and macroeconomic headwinds.

DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.

DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.